Key facts
- This page summarizes Todd Christopher Longsworth's Form 4 filing for NovoCure Ltd (NVCR).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 07 Mar 2022, 17:28.
Todd Christopher Longsworth - 03 Mar 2022 Form 4 Insider Report for NovoCure Ltd (NVCR)
- Reporting relationship
- General Counsel
- Issuer ticker
- NVCR
- Reported as of
- 03 Mar 2022
- Net transaction value
- +$271,669
- SEC form
- 4
- Accepted by SEC
- 07 Mar 2022, 17:28:25 UTC
- Prior SEC filing
- 08 Jul 2021
- Next SEC filing
- 09 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Steven Robbins, Attorney in Fact for Todd Longsworth
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Todd Christopher Longsworth filed Form 4 for NovoCure Ltd (NVCR) on 07 Mar 2022.
Change
- Previous filing in this sequence was filed on 08 Jul 2021.
- Current net transaction value: +$271,669.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NVCR
transaction
Ordinary Shares
Sale
- Transaction value
- $81,501
- Shares
- -1,094
- Change %
- -1.6%
- Price
- $74.50
- Shares after
- 66,774
- Date
- 03 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
NVCR
transaction
Ordinary Shares
Sale
- Transaction value
- $138,913
- Shares
- -1,973
- Change %
- -3%
- Price
- $70.41
- Shares after
- 64,801
- Date
- 04 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NVCR
transaction
Derivative
Options to Buy Ordinary Shares
Award
- Transaction value
- $492,083
- Shares
- +6,106
- Change %
- Price
- $80.59
- Shares after
- 6,106
- Date
- 03 Mar 2022
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 6,106
- Exercise price
- $80.59
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Footnote F2
Options to buy 6,106 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates.